This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ESMO-Asia, Singapore 22-24 November 2019

Interim analysis from a Phase IIIb, open-label study of afatinib in EGFR-TKI-naïve patients with EGFR mutation-positive (EGFRm+) NSCLC​

Filippo De Marinis, Konstantin K. Laktionov, Artem Poltoratskiy, Inna Egorova, Maximilian Hochmair, Antonio Passaro, Maria Rita Migliorino, Giulio Metro, Maya Gottfried, Daphne Tsoi, Gyula Ostoros, Simona Rizzato, GuzelZ. Mukhametshina, Michael Schumacher, Silvia Novello, Rafal Dziadziuszko, Wenbo Tang, Laura Clementi, Agnieszka Cseh, Dariusz Kowalski

1200.55_esmo-asia_2019_poster.jpg

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

The value of real-world evidence to clinical practice

Real-world evidence complements clinical trials by providing information on the effectiveness and side-effect profile of therapies in patients treated in routine clinical practice.

The value of real-world evidence to clinical practice

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY.

image